Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Operating Expenses (2020 - 2023)

Terns Pharmaceuticals' Operating Expenses history spans 4 years, with the latest figure at $63.5 million for Q4 2023.

  • For Q4 2023, Operating Expenses rose 277.33% year-over-year to $63.5 million; the TTM value through Dec 2023 reached $63.5 million, up 2.37%, while the annual FY2025 figure was $110.1 million, 8.1% up from the prior year.
  • Operating Expenses reached $63.5 million in Q4 2023 per TERN's latest filing, up from $16.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $63.5 million in Q4 2023 to a low of $8.7 million in Q3 2020.
  • Average Operating Expenses over 4 years is $16.4 million, with a median of $13.3 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: grew 3.98% in 2022, then surged 277.33% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $8.8 million in 2020, then skyrocketed by 69.69% to $14.9 million in 2021, then rose by 13.11% to $16.8 million in 2022, then soared by 277.33% to $63.5 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Operating Expenses are $63.5 million (Q4 2023), $16.8 million (Q4 2022), and $17.3 million (Q3 2022).